Overview

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health
Hackensack University Medical Center
Treatments:
Bortezomib
Melphalan